Colorectal Oncology最新文献_第2页

Factors associated with efficacy of FOLFIRI/aflibercept in patients with metastatic colon cancer 与转移性结肠癌患者FOLFIRI/aflibercept疗效相关的因素

Colorectal Oncology Pub Date : 2019-06-16 DOI: 10.17650/2220-3478-2019-9-2-29-37

M. Fedyanin, L. Vladimirova, V. Chubenko, L. Zagorskaya, A. Belyaeva, L. Bolotina, F. Moiseenko, O. L. Fakhrutdinova, S. Belukhin, A. Zhabina, L. Khalikova, V. Moiseenko, А. Meshcheryakov, E. Artamonova, I. Pokataev, A. Khasanova, A. Belonogov, Kh.Sa. Musaeva, O. Novikova, I. Stradaeva, I. Popova, G. Mukhametshina, R. Orlova, S. Erdniev, A. Ivanova, A. Androsova, P. Feoktistova, E. Kuzmina, E. Karabina, O. Nekrasova, V. Sherstnev, A. Mishchenko, L. A. Mukova, B. Kertiev, G. I. Kosar, S. N. Osodoeva, A. I. Kats, R. Malina, A. Tryakin, S. Tjulandin

{"title":"Factors associated with efficacy of FOLFIRI/aflibercept in patients with metastatic colon cancer","authors":"M. Fedyanin, L. Vladimirova, V. Chubenko, L. Zagorskaya, A. Belyaeva, L. Bolotina, F. Moiseenko, O. L. Fakhrutdinova, S. Belukhin, A. Zhabina, L. Khalikova, V. Moiseenko, А. Meshcheryakov, E. Artamonova, I. Pokataev, A. Khasanova, A. Belonogov, Kh.Sa. Musaeva, O. Novikova, I. Stradaeva, I. Popova, G. Mukhametshina, R. Orlova, S. Erdniev, A. Ivanova, A. Androsova, P. Feoktistova, E. Kuzmina, E. Karabina, O. Nekrasova, V. Sherstnev, A. Mishchenko, L. A. Mukova, B. Kertiev, G. I. Kosar, S. N. Osodoeva, A. I. Kats, R. Malina, A. Tryakin, S. Tjulandin","doi":"10.17650/2220-3478-2019-9-2-29-37","DOIUrl":"https://doi.org/10.17650/2220-3478-2019-9-2-29-37","url":null,"abstract":"Objective: to identify factors associated with efficacy of an aflibercept-chemotherapy combination in patients with metastatic colon cancer. Materials and methods. This retrospective multicenter study was conducted in 20 clinics from 15 regions of the Russian Federation. The main efficacy outcome was progression-free survival (PFS). We performed univariate and multivariate analysis to assess the impact of various factors of PFS. Results. Two hundred and fifty-seven patients received aflibercept-containing chemotherapy; of them, 175 participants (68.1 %) received it as a second-line therapy. The objective response rate and median PFS were 18.7% and 5 months (95% confidence interval (CI) 4.2—5.8) respec -tively. The following factors were found to have a positive effect of PFS at multivariate analysis: grade I—II adverse events to aflibercept therapy (hazard ratio (HR) 0.58; 95 % CI 0.38—0.89; p = 0.01), therapy for concomitant diseases (HR 0.47; 95 % CI 0.29—0.76; p = 0.002), and ECOG performance status of 0 (HR 0.53; 95 % CI 0.34—0.81; p = 0.004). Patient with all 3 factors present had median PFS of 9 months, whereas patients without them demonstrated PFS of only 3 months (HR 1.9; 95 % CI 1.5—2.6; p <0.001). Conclusions. Satisfactory performance status, adequate therapy for concomitant diseases, and adverse events to aflibercept therapy were associated with better PFS in patients receiving aflibercept-containing chemotherapy.","PeriodicalId":225735,"journal":{"name":"Colorectal Oncology","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130040645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Implementation of laparoscopic approach in colorectal cancer surgery — a single center’s experience 腹腔镜入路在结直肠癌手术中的实施-单中心经验

Colorectal Oncology Pub Date : 2018-12-27 DOI: 10.17650/2220-3478-2018-8-4-60-64

V. Unguryan, A. Babich, Y. Pobedintseva, V. A. Kudlachev, E. Kruglov

{"title":"Implementation of laparoscopic approach in colorectal cancer surgery — a single center’s experience","authors":"V. Unguryan, A. Babich, Y. Pobedintseva, V. A. Kudlachev, E. Kruglov","doi":"10.17650/2220-3478-2018-8-4-60-64","DOIUrl":"https://doi.org/10.17650/2220-3478-2018-8-4-60-64","url":null,"abstract":"Objective : to evaluate complication rate, surgical operation time, mortality rate implementing minimally invasive surgical technique in colon and rectal surgery — a single cancer’s center experience. Matherials and methods . 124 patients underwent surgery in the period from 2016 to 2018 using laparoscopic technique for colorectal cancer. All patients were divided on 3 equal groups, depending on the time required to master laparoscopic technique: group A (1—40 procedure), group B (41—80 procedure) and group C (81—124 procedure). Outcome measures included operation time, mortality rate, readmission and postoperative complication rates, number of lymph nodes removed and time of impatient care. Results . Main outcome variables (operation time, number lymph nodes removed, time of impatient care, mortality rates, postoperative complication rates) reach a plateau in the learning curve after 54 operation. The study showed that the incidence of postoperative complications in all groups was 11.4 %, while the significantly high level of complications was in group A — 17.5 % (p = 0.023). Postoperative mortality in groups A and B was 2.5 % and 2.5 %, respectively. Conclusion . It is shown that the introduction of minimally invasive technologies into colorectal cancer surgery is relatively safe and possible under the given conditions, while the time of mastering the technique is comparable with the data available in the literature.","PeriodicalId":225735,"journal":{"name":"Colorectal Oncology","volume":"86 1-2 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123606814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Successful treatment of rectal cancer complicated by bladder invasion, peritumorally abscess, and a fistula in the anterior abdominal wall (case report) 直肠癌合并膀胱侵犯、瘤周脓肿、前腹壁瘘的成功治疗(附1例报告)

Colorectal Oncology Pub Date : 2018-12-27 DOI: 10.17650/2220-3478-2018-8-4-65-68

V. Ivanov, S. Gordeev, S. Tkachev, A. Perevoshchikov

引用次数: 0

Circulating tumor DNA as a marker of residual tumor in colon cancer 循环肿瘤DNA作为结肠癌残留肿瘤的标志物

Colorectal Oncology Pub Date : 2018-11-03 DOI: 10.17650/2220-3478-2018-8-3-11-16

M. Fedyanin, Kheda Elsnukaeva, V. Aliev, T. S. Ayrapetyan, A. Polyakov, E. V. Moroz, V. A. Uymanov, U. Boyarskikh, A. Kechin, M. Filipenko, S. Tjulandin

引用次数: 0

Role of antiangiogenic agents in the treatment of metastatic colorectal cancer 抗血管生成药物在转移性结直肠癌治疗中的作用

Colorectal Oncology Pub Date : 2018-05-29 DOI: 10.17650/2220-3478-2018-8-1-11-18

M. Zabelin, S. Gordeev, L. Petrov, A. Kostin, S. E. Varlamova

{"title":"Role of antiangiogenic agents in the treatment of metastatic colorectal cancer","authors":"M. Zabelin, S. Gordeev, L. Petrov, A. Kostin, S. E. Varlamova","doi":"10.17650/2220-3478-2018-8-1-11-18","DOIUrl":"https://doi.org/10.17650/2220-3478-2018-8-1-11-18","url":null,"abstract":"Objective: to estimate the average duration of therapy with Avastin (bevacizumab) in patients with metastatic colorectal cancer (mCRC) in the daily clinical practice of cancer care facilities in Russia. Methods. The observational program is being implemented on the initiative of the Russian Medical Academy for Postgraduate education RF (Moscow) and it is based on the results of treating patients with mCRC in 24 clinical centers from different regions of the Russian Federation. The observational program includes patients receiving drug treatment for mCRC in accordance with the local standards and guidelines. Program patient enrolment has not been over yet. The paper presents preliminary results. Results. As of March 1, 2013, the program enrolled 117 patients, including 43 with rectal cancer and 74 with colon cancer. At baseline 70 (60%) patients had synchronous distant metastases and 47 (40%) patients developed synchronous distant metastases after primary radical surgery. At the analysis, 112 patients were treated with bevacizumab in combination with different chemotherapy (CT) regimens; 25 patients received more than the 1 line of CT, in 8 of them bevacizumab was discontinued (because of disease progression in 6 cases); 33 (29%) patients were switched to bevacizumab monotherapy during treatment. The effect of CT with simultaneous administration of 7–10 infusions of bevacizumab was preserved in 73% of the patients; 4 and 27% showed complete and partial responses, respectively; stabilization was noted in 42%. Sixty-three (56%) patients received symptomatic therapy. Adverse events were observed in 18 (16%) pati- ents, 13 of them had grade 4 reactions. Conclusion. Targeted therapy with bevacizumab is in considerable use in the health care facilities of the Russian Federation. The addi- tion of bevacizumab to CT does not increase toxicity of CT. The combination of bevacizumab and standard CT regimens can achieve high disease control rates.","PeriodicalId":225735,"journal":{"name":"Colorectal Oncology","volume":"92 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133986278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Comparative analysis of quality of life after laparoscopic and open procedures for upper and middle rectal cancer 上、中段直肠癌腹腔镜与开放式手术后生活质量的比较分析

Colorectal Oncology Pub Date : 2018-05-29 DOI: 10.17650/2220-3478-2018-8-1-28-33

A. Karachun, E. Petrova, Sinenchenko Gi, D. Samsonov, Y. Pelipas

引用次数: 4